CURE’s bladder cancer page is a go-to resource for oncology news and updates in the world of bladder cancer. Here, readers will find cancer articles, videos, podcasts, and more with expert insight into the latest treatments and research in bladder cancer.
September 17th 2021
Clinical trials that are designed to ask patients with bladder, kidney and prostate cancer about their smoking status may help patients better understand what to expect from their treatment based on their smoking habits.
September 1st 2021
Patients with Bacillus Calmette Guérin-unresponsive carcinoma in-situ will be treated at the University of Chicago in a Theralase study.
August 31st 2021
Keytruda is now indicated for the treatment of locally advanced or metastatic urothelial carcinoma, a type of bladder cancer, although an unmet need remains in the treatment of these patients.
August 23rd 2021
A recently approved antibody-drug conjugate provides another much-needed treatment choice for patients with locally advanced and metastatic urothelial cancer.
August 20th 2021
Preliminary results of the phase 2 trial assessing the safety and efficacy of Cosela with gemcitabine/platinum-based chemotherapy and Bavencio maintenance therapy for metastatic bladder cancer are expected to be released in the second half of 2022.
August 20th 2021
The FDA granted approval to Opdivo as an adjuvant treatment in patients with high-risk urothelial carcinoma.
July 29th 2021
Intravesical therapy for patients with non-muscle invasive bladder cancer was found to have an impact on patients’ social, emotional and physical health.
July 29th 2021
In this episode of the “CURE® Talks Cancer” podcast, a cancer survivor who served in the Vietnam War shares the story of his Agent Orange exposure and bladder cancer.
July 20th 2021
Smoking cigarettes could lead to a four-fold increased risk of recurrence in patients with a previous diagnosis of non-muscle invasive bladder cancer.
July 19th 2021
An analysis showed that glycemic index – but not glycemic load or total carbohydrate intake – significantly increased the risk of developing bladder cancer.
July 9th 2021
Approximately 18 months after granting Padcev an accelerated approval, the Food and Drug Administration granted a regular approval to the treatment for certain previously treated patients with locally advanced or metastatic urothelial carcinoma.
July 7th 2021
Results demonstrating the efficacy of Bavencio highlight the importance of incorporating recent clinical trial successes into the treatment conversation.
July 7th 2021
Agent Orange exposure impacted millions of U.S. military personnel during the Vietnam War. The chemical may have led to bladder cancer diagnoses later in life.
July 4th 2021
Keytruda plus gemcitabine and higher doses of radiotherapy showed promising efficacy and safety results in patients with muscle-invasive bladder cancer.
June 30th 2021
Patients who tested positive for the biomarker circulating tumor DNA (ctDNA) had improved disease-free and overall survival after receiving Tecentriq.
June 10th 2021
A combination of treatment with bladder-saving surgical resection, Opdivo and chemotherapy yielded positive results in patients with muscle-invasive bladder cancer.
June 7th 2021
The study’s lead author noted that the data support giving patients with advanced bladder cancer chemotherapy to get control of the disease and then maintaining that control with maintenance Bavencio.
May 25th 2021
Some of the most popular YouTube videos about bladder cancer are of poor quality, spread misinformation and have commercial bias.
May 24th 2021
A retirement counselor with bladder cancer shares the story of his diagnosis and his thoughts on treatment.
May 13th 2021
A roundup of some of CURE®’s latest news and updates for patients with bladder cancer in honor of Bladder Cancer Awareness Month this May.
May 5th 2021
FDA committee members recently voted in favor of upholding Tecentriq’s accelerated approval indication for the first-line treatment of certain adults with locally advanced or metastatic urothelial carcinoma who are ineligible for standard chemotherapy.
April 22nd 2021
In this episode of the “CURE® Talks Cancer” podcast, Henry Scowcroft discusses his experiences writing a book about his late wife’s cancer journey and offers advice for other caregivers.
April 13th 2021
Several factors were associated with patients undergoing radical nephrectomy compared with radical nephroureterectomy including Black race, large tumors, advanced tumor stage and high-grade tumors.
April 13th 2021
Trodelvy has received accelerated approval from the FDA for the treatment of patients with advanced urothelial cancer.
April 12th 2021
Adjusting the dose of cisplatin, when added to regular doses of Abraxane and gemcitabine, led to similar survival rates when treating patients with advanced/metastatic urothelial carcinoma, which may help to address issues commonly seen with patients who cannot tolerate cisplatin such as renal dysfunction.
March 9th 2021
If patients were receiving Tecentriq for prior platinum-based treated metastatic urothelial carcinoma, they should discuss next best steps with their health care providers.
March 4th 2021
While it is important to educate oneself after receiving a diagnosis of cancer, it’s also critical to know when to step away and find a balance between cancer and life, according to Diane Zipursky-Quale.
February 24th 2021
To discuss the projected rise in bladder cancer cases in 2021, CURE® spoke with Bladder Cancer Advocacy Network (BCAN) co-founder Diane Zipursky-Quale, who offered some insight on why the numbers continue to rise, and provides some hope in the form of educational programs offered by her organization.
February 15th 2021
Treatment with Padcev, compared to chemotherapy, continues to show better results in patients with advanced urothelial carcinoma who had previously received certain therapies.